Cas:96179-45-2 [3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate manufacturer & supplier

Chemical Name:[3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate

CAS.NO:96179-45-2

Synonyms:Benzosalicylanilide |A-phenylbutyrate;Naphthol AS |A-phenylbutyrate

Molecular Formula:C₂₇H₂₃NO₃

Molecular Weight:409.47600

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.40000

Exact Mass:409.16800

LogP:6.09340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Benzosalicylanilide |A-phenylbutyrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Naphthol AS |A-phenylbutyrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Naphthol AS |A-phenylbutyrate Use and application,Benzosalicylanilide |A-phenylbutyrate technical grade,usp/ep/jp grade.

Related News: At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances. [3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate manufacturer At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances. [3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate supplier f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. [3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate vendor f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. [3-(phenylcarbamoyl)naphthalen-2-yl] 4-phenylbutanoate factory In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.